PTC Therapeutics (NASDAQ: PTCT) is a global biopharmaceutical company focused on the discovery, development and commercialization of novel medicines using expertise in RNA biology. PTC’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC’s mission is focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. PTC’s Translarna has been approved in Europe for the treatment of nonsense mutation Duchenne muscular dystrophy and its EMFLAZA is approved in the United States for the treatment of Duchenne muscular dystrophy.